Saturday 17 October 2026
Export APUS’s income statement to Excel — free account
Apimeds Pharmaceuticals US, Inc.
APUS Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, EPS fell 352.7%, free cash flow fell 67.9% and total debt rose 2,468.3%, each against the same quarter a year earlier.
4.04
0.35
−7.97%
Follow APUS
Apimeds Pharmaceuticals US, Inc. (APUS) P/E ratio
Apimeds Pharmaceuticals US, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RDHL Redhill Biopharma Ltd. compare | n/m |
| INM InMed Pharmaceuticals Inc. compare | n/m |
| SNOA Sonoma Pharmaceuticals, Inc. compare | n/m |
| BFRI Biofrontera Inc. compare | n/m |
| APUS Apimeds Pharmaceuticals US, Inc. | n/m |
| BGXXQ Bright Green Corporation compare | n/m |
| YCBD cbdMD, Inc. compare | 41.2× |
| GELS Gelteq Limited compare | — |
| AKAN Akanda Corp. compare | — |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)